Literature DB >> 1492629

Clinical significance of the vertebral vein in prostate cancer metastasis.

Y Nishijima1, K Uchida, K Koiso, R Nemoto.   

Abstract

A total of 75 prostate cancer and 67 lung cancer patients with positive bone scintigrams were studied. The patterns of spread in the axial skeleton and pelvis were different between the groups. The differences in the distribution of bony metastases between prostate and lung are explained by the role of Batson's vertebral venous plexus. We developed an animal model of spinal bone metastasis to prove this route. As suspension of tumor cells was injected into the tail vein of mice with vena caval occlusion. This procedure reproducibly resulted in metastatic tumor growth in the lumbar region of the vertebral column. The prevalence of spinal bone metastasis is attributed to passage of tumor cells via the vertebral venous plexus.

Entities:  

Mesh:

Year:  1992        PMID: 1492629     DOI: 10.1007/978-1-4615-3398-6_9

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  3 in total

1.  Esophageal metastasis from prostate cancer: diagnostic use of reverse transcriptase-polymerase chain reaction for prostate-specific antigen.

Authors:  T Nakamura; H Mohri; M Shimazaki; Y Ito; T Ohnishi; Y Nishino; S Fujihiro; H Shima; T Matsushita; M Yasuda; H Moriwaki; Y Muto; T Deguchi
Journal:  J Gastroenterol       Date:  1997-04       Impact factor: 7.527

2.  Compressive loading at the end plate directly regulates flow and deformation of the basivertebral vein: an analytical study.

Authors:  Ming-Long Yeh; Michael H Heggeness; Hsiang-Ho Chen; Jennifer Jassawalla; Zong-Ping Luo
Journal:  J Orthop Surg Res       Date:  2006-12-27       Impact factor: 2.359

Review 3.  Cohesive cancer invasion of the biophysical barrier of smooth muscle.

Authors:  William L Harryman; Kendra D Marr; Daniel Hernandez-Cortes; Raymond B Nagle; Joe G N Garcia; Anne E Cress
Journal:  Cancer Metastasis Rev       Date:  2021-01-04       Impact factor: 9.264

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.